MTA2 and breast carcinoma: However, in a study reported recently, TRPS1-CHD4/NuRD(MTA2) complex represses TP63 expression by involving decommission of TP63 enhancer, leading to a reduction of the ΔNp63 level and could reduce cell migration and invasion of breast cancer cells [7], which might lead to the resistance to CHD4 suppression.